Table 2. Sensitivities and specificities for FGF19 to detect abnormal C4 levels.
| FGF19 (pg/ml) | C4 value (ng/ml) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|---|
| All patients | |||||
| ≤145 | >28 | 58 | 79 | 76 | 62 |
| ≤145 | >35 | 62 | 77 | 71 | 70 |
| ≤145 | >48 | 67 | 73 | 57 | 81 |
| ≤145 | >60 | 74 | 72 | 50 | 88 |
| ≤200 | >28 | 71 | 67 | 72 | 66 |
| ≤200 | >60 | 81 | 58 | 42 | 88 |
| Type 1 BAD | |||||
| ≤145 | >28 | 76 | 79 | 63 | 88 |
| ≤200 | >60 | 93 | 62 | 42 | 97 |
| Type 2 BAD | |||||
| ≤145 | >28 | 40 | 79 | 40 | 78 |
| ≤200 | >60 | 64 | 64 | 15 | 95 |
| Type 3 BAD | |||||
| ≤145 | >28 | 49 | 79 | 40 | 84 |
| ≤200 | >60 | 60 | 63 | 15 | 94 |
BAD, bile acid diarrhea; C4, serum 7α-hydroxy-4-cholesten-3-one; FGF19, fibroblast growth factor 19; PPV, positive predictive value; NPV, negative predictive value.